New User:

Forgot your password?

Stock Market & Financial Investment News

Sign up for a free trial to see the rest of the stories you've been missing.
May 22, 2015
10:35 EDTSQNMSequenom genetic test false positive highlighted in NBC Nightly News report
Recent studies have "cast doubt" on the reliability of pre-natal genetic tests such as Sequenom's MaterniT21 test, according to a report aired by NBC Nightly News. Reference Link
May 21, 2015
08:39 EDTIMGNNovartis initiates Phase 1 PCA062, triggering milestone payment to ImmunoGen
In a regulatory filing, ImmunoGen disclosed Novartis (NVS) Institutes for BioMedical Research notified ImmunoGen (IMGN) that Novartis had initiated Phase I, first-in-human clinical testing of a product candidate, PCA062, utilizing antibody-drug conjugate technology. Pursuant to the license taken under our 2010 Multi-Target Agreement, this start of clinical testing triggers a $5M milestone payment to ImmunoGen.
May 19, 2015
07:37 EDTDSCIDerma Sciences reports halfway point of enrollment in Phase 3 aclerastide study
Subscribe for More Information
07:28 EDTCCRNUBS to hold a conference
Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 19 at 8 am; not all company presentations may be webcasted. Webcast Link
06:21 EDTAMEDAmedisys management to meet with SunTrust
Meeting to be held in Boston on May 20 hosted by SunTrust.
May 14, 2015
07:40 EDTIMGNImmunoGen data 'impressive,' says Oppenheimer
Subscribe for More Information
May 13, 2015
17:41 EDTIMGNImmunoGen to present mirvetuximab data at 2015 ASCO meeting
Subscribe for More Information
May 12, 2015
07:35 EDTAMEDBofA/Merrill to hold a conference
Subscribe for More Information
May 11, 2015
07:09 EDTDSCIDerma Sciences sees FY15 revenue approx. $88.1M, consensus $88.2M
Subscribe for More Information
07:08 EDTDSCIDerma Sciences reports Q1 EPS (42c), consensus (48c)
Reports Q1 revenue $19.5M, consensus $19.89M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use